Sep 2026· Biochimica et biophysica acta. Molecular cell research· pp.
120226
· 0 citations· 58 references
Medicine
TL;DR
This review summarizes classic and recent findings on structural biology, PTM networks, mutation landscapes, oncogenic mechanisms, and therapeutic frontiers, highlighting TWIST1 as a target for precision oncology and therapy.
Abstract
TWIST1 is a deeply conserved basic helix-loop-helix (bHLH) transcription factor that has emerged as a central transcriptional regulator bridging developmental biology and cancer pathogenesis. This key regulator orchestrates mesoderm formation, neural crest migration, and craniofacial morphogenesis through precise dimerization-dependent mechanisms. The TWIST1 bHLH domain mediates DNA binding at E-box motifs (CANNTG), with its regulatory role determined by homodimer versus E-protein heterodimer formation. Recent reports demonstrate that post-translational modifications (PTMs) are critical for TWIST1 activity: diacetylation at K73/K76 by TIP60 recruits BRD8 to activate mesenchymal and MYC targets, whereas non-acetylated TWIST1 recruits the NuRD repressor complex to silence epithelial genes. Aurora kinase A (AURKA) phosphorylation at three sites stabilizes TWIST1, promotes homodimerization, and drives chemoresistance, while SETD6-mediated K33 methylation enhances EZH2 occupancy and H3K27me3 deposition at the LINC-PINT locus. Germline loss-of-function mutations clustered in the bHLH domain cause Saethre-Chotzen syndrome (SCS), an autosomal dominant craniosynostosis disorder characterized by protein degradation or impaired nuclear localization. Therapeutic targeting TWIST1 remains challenging due to the absence of deep binding pockets, but emerging strategies include harmine (a β-carboline alkaloid)-mediated proteasomal degradation, BRD4/TIP60/BRD8 axis inhibition, and transcription factor-targeted proteolysis-targeting chimeras (TF-PROTACs) employing DNA oligonucleotide warheads linked to E3 ligase ligands. This review summarizes classic and recent findings on structural biology, PTM networks, mutation landscapes, oncogenic mechanisms, and therapeutic frontiers, highlighting TWIST1 as a target for precision oncology and therapy.
Previous research has predominantly focused on the regulatory role of lncRNA HOTAIR in gene silencing by interacting with the Polycomb repressive complex 2 (PRC2), but its direct role as a transcriptional activator remains less well characterized. Here, our study reveals a novel regulatory mechanism of HOTAIR, which fa...
Yu-Yang Qian, Bo Wang, Guang-Song Su et al.· International Journal on Bio...· 0 citations
It is shown that p63 reorganizes 3D chromatin topology in squamous cell carcinoma through cooperation with the tumor-selective partner TF, FOXK1, which defines an epigenetic mechanism by which a lineage master TF and tumor-restricted partner TF reshape 3D chromatin structure to drive oncogenic transcription, with impli...
N. Jung, V. Lopez-Pajares, L. Donohue et al.· Science Advances· 0 citations
The SF3b complex is positioned as a disease-modifying hub at the intersection of RNA splicing and cancer biology, and highlights the opportunities and challenges associated with therapeutically targeting spliceosome components in oncology.
Shulin Li, Li-Tong Shang, Jia-Yi Yang et al.· Blood Advances· 0 citations
Findings establish α7 integrin as a key co-regulator of chromatin accessibility and gene transcription in HPV-negative HNSCC, acting through an AURKA-centered axis that couples adhesion signaling to cell cycle control and patient survival, and nominate AURKA, potentially targetable with clinical Aurora-A inhibitors suc...
Olegs Borodins, A. Vehlow, K. Sameith et al.· Signal Transduction and Targ...· 0 citations
Findings indicate that the c-Myc-CASC19/HDAC1-NPM1 axis acts as a potential prognostic biomarker candidate for GC and may represent a therapeutic vulnerability worthy of future investigation.